The grants will support the work of two distinguished scientists deeply engaged in novel cell and gene therapy research: Dr. Joseph Fraietta at the University of Pennsylvania, operating through the ACGT, and Dr. Pietro Genovese at the Dana-Farber Cancer Institute. These investigators are at the forefront of integrating sophisticated gene-editing tools into cancer treatment strategies, a field rapidly evolving with the advent of CRISPR and related technologies. Their collaborative efforts promise to yield new therapeutic modalities with potential applicability across a broad spectrum of malignancies, including notoriously difficult-to-treat solid tumors and hematologic cancers.

In recent years, gene editing has emerged as a transformative force in oncology, offering unparalleled precision in manipulating genetic material to enhance immune responses against cancer. Dr. Fraietta’s research harnesses a refined gene-editing technology known as base editing, which allows single-letter changes in DNA without inducing double-stranded breaks, thereby reducing off-target effects and improving safety profiles. Utilizing this approach, his team engineers CAR T cells—immune cells reprogrammed to recognize and destroy cancer cells—that are optimized to target tumors harboring KRAS mutations prevalent in approximately a quarter of human cancers, such as those affecting the lung, colon, and pancreas.

Moreover, Dr. Fraietta’s laboratory is pioneering the creation of “micropharmacies,” a novel cellular platform wherein genetically modified immune cells are designed to secrete therapeutic agents directly at tumor sites. This localized delivery system minimizes systemic toxicity and maximizes anti-tumor efficacy by concentrating immune-stimulatory molecules within the tumor microenvironment. Such precision medicine approaches could mitigate the side effects commonly associated with conventional chemotherapy and non-targeted immunotherapy regimens, offering patients more tolerable and effective treatment options.

Meanwhile, Dr. Genovese’s innovative strategy at Dana-Farber represents a paradigm shift in leukemia treatment. Instead of solely focusing on eradicating malignant cells, his research revolves around engineering “stealth” healthy blood cells capable of enduring aggressive chemotherapy and targeted cancer therapies. These modified cells evade immune detection and destruction, creating a protective reservoir of functional hematopoietic cells during treatment-induced cytotoxicity. This approach holds promise in reducing collateral damage to vital healthy cells, a significant limitation of current acute myeloid leukemia (AML) therapies, and could improve patient outcomes by preserving bone marrow function.

The financial backing from Swim Across America facilitates these exploratory, high-risk, high-reward projects that might otherwise struggle to secure funding. This underscores the critical role philanthropic organizations play in bridging the gap between foundational research and clinical application, especially in areas where conventional grant mechanisms may be insufficiently nimble or risk-averse. By investing in early-stage work, Swim Across America accelerates the translation of compelling scientific concepts into viable therapeutic innovations.

Rob Butcher, CEO of Swim Across America, emphasizes the transformative potential of gene-editing technologies in the fight against cancer. He highlights how these grants empower scientists to expedite the development of next-generation treatments, building upon the organization’s successful history of supporting research that contributed to the approval of landmark immunotherapy drugs like Keytruda and Opdivo. These new investments aim to catalyze a wave of breakthroughs that could fundamentally alter cancer therapy paradigms and substantially improve patient quality of life.

The broader implications of this research extend beyond the development of novel therapies. Enhanced gene-editing methodologies and cellular engineering techniques also facilitate advancements in early cancer detection, minimal residual disease monitoring, and personalized cancer vaccine design. These comprehensive applications point toward a future where cancer management is increasingly tailored to the genetic and immunologic profile of each patient, fostering more durable remissions and potentially curative outcomes.

Since its inception in 1987, Swim Across America has raised over $100 million to support cancer research, consistently funding projects that push the boundaries of scientific knowledge and clinical care. The organization hosts a wide variety of swimming events across the United States, generating awareness and funds through the enthusiastic participation of Olympians and community members alike. Its unique model of combining athleticism with philanthropy has made it a keystone in the cancer research funding ecosystem, particularly for innovative, early-phase studies.

Dr. Fraietta’s work echoes this spirit of innovation by targeting the notorious KRAS oncogene, a historically “undruggable” target responsible for driving tumorigenesis in a significant subset of cancer patients. Through base editing of CAR T cells, his research aims to circumvent traditional therapeutic challenges associated with KRAS mutations, potentially unlocking new avenues for treating some of the most lethal cancers. The integration of micropharmacy concepts further elevates the approach, marrying genetic precision with functional immunotherapy.

At the same time, Dr. Genovese’s “stealth cell” approach challenges established oncologic dogma by seeking to preserve healthy hematopoiesis amidst aggressive treatment regimens. Acute myeloid leukemia, characterized by the rapid proliferation of malignant myeloid cells, requires intensive chemotherapy that often devastates normal bone marrow function. Engineering cells that can evade destruction offers a compelling solution to reduce treatment-related toxicity, improve recovery, and enhance overall survival rates for patients with AML and potentially other blood cancers.

The Swim Across America grants epitomize a strategic investment in the future of cancer treatment, supporting research that not only explores advanced gene-editing techniques but also aims to address pressing clinical challenges such as treatment resistance, tumor heterogeneity, and therapy-related adverse effects. This funding paves the way for integrating these modalities into clinical trials and, eventually, routine care, exemplifying the dynamic interplay between scientific innovation and patient-centered application.

Through these efforts, Swim Across America continues to champion a model of research funding that catalyzes transformative discoveries, fosters collaborations between academic and clinical researchers, and ultimately strives to deliver lifesaving treatments to cancer patients. The hope is that these pioneering projects spearheaded by Drs. Fraietta and Genovese will usher in a new era of precision oncology, defined by safer, more effective, and personalized gene- and cell-based therapies.

Subject of Research:
Advancement of novel gene and base editing techniques for cancer therapy, including engineered CAR T cell therapies targeting KRAS mutations and development of resilient hematopoietic cell therapies for acute myeloid leukemia.

Article Title:
Swim Across America Awards $900,000 to Drive Breakthrough Gene-Editing Cancer Therapies at University of Pennsylvania and Dana-Farber

News Publication Date:
Not specified in the provided content.

Web References:
https://swimacrossamerica.org
https://mediasvc.eurekalert.org/Api/v1/Multimedia/99bff3d1-5fd5-4380-b9e2-0f1437d04b2b/Rendition/low-res/Content/Public

Image Credits:
University of Pennsylvania

Keywords:
Gene editing, base editing, CAR T cells, KRAS mutations, acute myeloid leukemia, stealth hematopoietic cells, Swim Across America, Alliance for Cancer Gene Therapy, Dana-Farber Cancer Institute, immunotherapy, cancer research funding, cellular therapy, targeted cancer treatments

CAR-T therapy has garnered significant attention in the oncological community because of its tailor-made approach to treating cancer. By engineering a patient’s own T cells, clinicians can magnify their ability to seek and destroy malignant cells. However, the full therapeutic potential of CAR-T cells is often curtailed by challenges posed by tumor microenvironments. Cancerous cells can create hostile conditions, leading to T cell exhaustion and diminished anticancer responses over time. The current research addresses these shortcomings by proposing gene modifications that render CAR-T cells both more resilient and effective against tumors.

Researchers employed the CRISPR screening technique—a groundbreaking method that allows scientists to systematically disable individual genes within the cells—to spotlight candidates that might enhance CAR-T therapies. By “knocking out” various genes, the researchers explored which modifications could contribute to superior T cell performance. Their investigations highlighted the CUL5 gene as a critical factor; its downregulation resulted in an extended life span and sustained activity of CAR-T cells.

The role of CUL5 in cellular biology is significantly based on its involvement in the ubiquitin-proteasome system, a vital process where proteins are tagged for degradation. The findings suggest that when CUL5 is inhibited, signaling pathways that facilitate T cell growth, specifically the JAK-STAT pathway, are activated in a more sustained manner. This pathway is essential for various immune functions, including cell growth and differentiation. Therefore, less CUL5 activity can lead to enhanced proliferation and activity of CAR-T cells, potentially allowing these engineered immune cells to effectively continue fighting cancer for longer periods.

In preclinical studies involving mice with B-cell lymphoma, researchers demonstrated that CUL5-deficient CAR-T cells significantly outperformed their conventional counterpart. In these trials, tumors treated with the modified CAR-T cells not only shrank more effectively but also showed a reduced rate of relapse. This provides compelling evidence that manipulating the expression of specific genes, like CUL5, can dramatically improve the therapeutic window of CAR-T therapies and may extend their applicability to a broader array of cancers.

Although current practices for creating CUL5-deficient CAR-T cells involve electroporation, this technique carries risks of cellular damage and is impractical for large-scale clinical applications. The innovative approach adopted by the Nagoya University researchers circumvents this limitation. By leveraging viral vectors to deliver genetic material for CUL5 attenuation, the research team successfully demonstrated that CAR-T cells maintain their viability and functional capacity post-modification.

The implications of this research extend far beyond hematological cancers, potentially unlocking new strategies for tackling solid tumors—historically among the most challenging types to treat with CAR-T cell therapies. Researchers are now keen to investigate whether this gene-modification technique can be extrapolated to other oncological contexts, enabling more comprehensive cancer treatment modalities.

Through this study, the team not only elucidates the pivotal role of the CUL5 gene in the context of T cell functionality but also emphasizes the power of genetic engineering in oncology. Given the complexity of cancer biology and the plasticity of the tumor microenvironment, targeted gene interventions could become a cornerstone of future cancer therapies.

As the research team continues to explore this promising field, the prospect of harnessing gene editing and viral delivery mechanisms opens up a new frontier in personalized medicine. By optimizing CAR-T cell therapies through genetic modifications, clinicians may be able to offer improved outcomes for patients facing daunting diagnoses and enhance the overall efficacy of cancer immunotherapy options.

In light of these advances, further studies will undoubtedly seek to answer critical questions surrounding the safety and long-term effects of such engineered therapies. Bridging the gap between laboratory findings and clinical application remains a priority for researchers, as they aspire to develop novel, personalized approaches to cancer treatment that can be easily adopted in clinical settings.

This pivotal research may inspire a new wave of investigation into gene-based therapies, reflecting growing interest in the intersection of genetics and immunotherapy as a viable pathway toward enhanced cancer care. As scientists deepen their understanding of the molecular mechanics underlying immune cell activity, the timelines for bringing innovative treatments into the hands of oncologists may shorten considerably, invigorating hope for patients and families confronting significant medical challenges.

With these innovations, the future holds promise for a new era in cancer treatment—an era where engineered immune cells can be tailored not just to act against cancer but to thrive in its presence, turning the tide in the relentless battle against this pervasive illness.

Subject of Research: Gene-modified CAR-T cell therapy
Article Title: Cullin-5 deficiency promotes chimeric antigen receptor T cell effector functions potentially via the modulation of JAK/STAT signaling pathway
News Publication Date: October 2023
Web References: DOI Link
References: Nature Communications
Image Credits: Reiko Matsushita

Keywords: Cancer, Gene Therapy, CAR-T Cells, CUL5, Immunotherapy, Hematologic Malignancies, CRISPR, JAK-STAT Pathway.

Cas12a represents a significant evolution in genome-editing technology, especially compared to its predecessor, Cas9, which has long been considered the standard in genetic manipulation techniques. While Cas9 has proven effective in many applications, researchers at ONJCRI and WEHI have demonstrated that Cas12a offers enhanced precision and efficiency, allowing for the simultaneous deletion of multiple genes. This capability could dramatically accelerate the pace of discovery in cancer research, providing a tool that is not only powerful but also versatile.

The utility of Cas12a in research is complemented by the novel mouse models created by the researchers, which incorporate unique Cas12a-compatible whole-genome CRISPR libraries. These libraries enable scientists to effectively identify and characterize genes implicated in the acceleration of lymphoma growth. By utilizing these tools, researchers can gain deeper insights into the genetic factors that contribute to cancer progression, ultimately informing the development of more effective therapeutic strategies.

The implications of this research extend far beyond basic science; they hold significant promise for translational medicine. The ultimate goal of employing these advanced gene-editing tools is to facilitate the development of targeted cancer therapies that can be applied in clinical settings. As the science behind CRISPR continues to evolve, understanding both its capabilities and limitations will be crucial in making it a viable option for cancer treatment.

Dr. Eddie La Marca, a postdoctoral researcher involved in the project, expressed optimism about the potential of Cas12a in preclinical models. He stated, “This is the first time Cas12a has been used in pre-clinical studies, which will significantly enhance our genome engineering capabilities. Experimentation with Cas12a provides us with a level of efficiency that will allow researchers to delete multiple genes concurrently.” This advancement is expected to open new avenues for exploring the genetic underpinnings of various diseases, potentially leading to new therapeutic interventions.

Notably, the integration of Cas12a with other genome editing technologies has allowed researchers to employ multiplexed gene manipulation techniques effectively. This innovative approach enables simultaneous activation and deactivation of different genes, a feat that could vastly improve the modeling of complex genetic disorders. Co-lead researchers Wei Jin and Dr. Yexuan Deng explained the significance of their findings, highlighting that the combination of Cas12a with modified Cas9 models allows for a more nuanced manipulation of the genome.

A key aspect of this research is the potential for broad application in the fight against a range of cancers. Professor Marco Herold, the CEO of ONJCRI and a leading voice in the field of cancer medicine, has been vocal about the importance of this work in advancing gene editing techniques. He believes that the Cas12a preclinical model, when combined with the novel screening libraries, provides a powerful toolkit for researchers dedicated to unraveling the complexities of oncogenesis.

The research conducted at ONJCRI is not merely confined to laboratory findings; it aims to liaise closely with clinical applications. As scientists gain deeper insights into the molecular biology of cancer, the methodologies developed through this study can be translated into therapies that may directly benefit patients. According to Professor Herold, the Cas12a preclinical model will be instrumental in understanding how such CRISPR tools could transition into clinical practice, marking a critical step forward in personalized medicine.

Moreover, the financial backing from the National Health and Medical Research Council and Phenomics Australia underscores the significance of this research initiative. The funding received enables researchers to pursue expansive studies that might lead to significant breakthroughs in cancer therapy and understanding of genetic diseases. With the continuous evolution of gene-editing technologies, the era of translating laboratory findings into effective treatments is becoming increasingly tangible.

The team’s work has garnered attention not only within the scientific community but also from the media, encouraging further exploration of gene-editing tools like Cas12a. Enhanced understanding of the mechanisms driving cancer through advanced techniques will help in building a more effective arsenal for oncologists battling this formidable disease. As research progresses, it is expected that these insights will pave the way for therapeutic innovations that can save lives.

The study published in Nature Communications marks a significant milestone in the field of genetic research. As researchers continue to unlock the mysteries of human cells through such innovative technologies, the path to understanding and potentially eradicating cancer becomes clearer. Collaborative efforts like this emphasize the importance of working across institutions and disciplines, harnessing a diverse range of expertise to tackle one of the most pressing health challenges of our time.

In conclusion, the advancements presented by researchers from the Olivia Newton-John Cancer Research Institute, WEHI, and Genentech illustrate a remarkable leap in the realm of gene editing. Their work on Cas12a raises exciting possibilities for cancer research, offering tools that could radically change the landscape of how genetic diseases are studied and treated. The integration of engineering enzymes with advanced screening libraries exemplifies the innovative spirit driving contemporary scientific inquiry, ultimately moving us closer to a future where gene editing plays a pivotal role in healthcare solutions.

Subject of Research: Cancer Research, Gene Editing
Article Title: Australian researchers enhance next-generation gene-editing technologies for cancer and medical research
News Publication Date: 30-Jan-2025
Web References: Nature Communications
References: Khan, S., Mahmood, M.S., Rahman, S.u. et al. CRISPR/Cas9: the Jedi against the dark empire of diseases. J Biomed Sci 25, 29 (2018).
Image Credits: Not Applicable

Keywords: Gene editing, Cancer research, Cas12a, CRISPR technology, Genetic disorders, Oncology, Genome manipulation, Preclinical models, Therapeutic development, Molecular biology, Genetic factors, Translational medicine.